Press Releases

Rheumatoid Arthritis Drugs Market Size to Worth Around US$ 70 Bn by 2030

The global rheumatoid arthritis drugs market size is expected to reach USD 70 Billion by 2030, with a CAGR of 1.72% from 2022 to 2030.

Share This Article
[150+ Pages Report] As per the latest Research and survey report issued by Precedence Research, the global rheumatoid arthritis drugs market was valued at around USD 60.02 billion in 2021 and is expected to register revenues worth USD 70 billion by the end of 2030, growing at an exceptional CAGR of approximately 1.72% between 2022 and 2030.

Rheumatoid Arthritis Drugs

Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1755

Rheumatoid Arthritis Drugs Market Report Scope

A recent study by Precedence Research on the rheumatoid arthritis drugs market offers a forecast for 2022 and 2030. The study analyzes crucial trends that are currently determining the growth of the rheumatoid arthritis drugs market.

This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of rheumatoid arthritis drugs. The study also provides the dynamics that are responsible for influencing the future status of the rheumatoid arthritis drugs market over the forecast period.

A detailed assessment of the rheumatoid arthritis drugs market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the rheumatoid arthritis drugs market along with their product portfolio enhances the reliability of this comprehensive research study.

Competition Landscape

The report has engulfed a chapter on the global electric vehicle market’s competitive landscape, which provides detailed analysis and insights on companies offering electric vehicle. Profiles of key companies, along with a strategic overview of their M&A and expansion plans across geographies, have been delivered in this chapter. This chapter is priceless for report readers, as its enables them in gauging their growth potential in the market and implement key strategies for extending their market reach.

This chapter offers key recommendations for both new and existing market participants, enabling them to emerge sustainably and profitably. Intelligence on the market players has been delivered on the basis of their product overview, SWOT analysis, key developments, key financials and company overview. Occupancy of these market participants has been tracked by the report and portrayed via an intensity map.

Read Also@ Geriatric Care Services Market Size to Worth Around US$ 1754.1 Bn by 2030

some of the prominent players in the rheumatoid arthritis drugs market include:

  • AbbVie
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • UCB S.A.
  • Johnson & Johnson Services, Inc.
  • Amgen, Inc.

Rheumatoid Arthritis Drugs Market Segments

By Molecule

  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
      • TNF-α antagonists
      • T-cell inhibitors
      • CD20 antigen
      • JAK inhibitors
      • anti-IL6 biologics
    • Biosimilars
      • CD20 antigen
      • TNF-α antagonists

By Sales Channel

 By Route of Administration

  • Oral
  • Parenteral

Regional Segmentation

  • Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
  • Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
  • North America [United States, Canada, Mexico]
  • South America [Brazil, Argentina, Columbia, Chile, Peru]
  • Middle East & Africa [GCC, North Africa, South Africa]

Regional Analysis

The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2022 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.

The report provides in-depth segment analysis of the global rheumatoid arthritis drugs market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the rheumatoid arthritis drugs market.

The report includes country-wise and region-wise market size for the period 2022-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2022-2030.

Why should you invest in this report?

If you are aiming to enter the global rheumatoid arthritis drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for rheumatoid arthritis drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Rheumatoid Arthritis Drugs Market 

5.1. COVID-19 Landscape: Rheumatoid Arthritis Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Rheumatoid Arthritis Drugs Market, By Molecule

8.1. Rheumatoid Arthritis Drugs Market, by Molecule, 2022-2030

8.1.1 Pharmaceuticals

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Biopharmaceuticals

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel

9.1. Rheumatoid Arthritis Drugs Market, by Sales Channel, 2022-2030

9.1.1. Prescription

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Over-the-Counter (OTC)

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Rheumatoid Arthritis Drugs Market, By Route of Administration 

10.1. Rheumatoid Arthritis Drugs Market, by Route of Administration, 2022-2030

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Parenteral

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Rheumatoid Arthritis Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.1.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

Chapter 12. Company Profiles

12.1. AbbVie

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Boehringer Ingelheim GmbH

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Novartis AG

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Regeneron Pharmaceuticals, Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pfizer, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bristol-Myers Squibb Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. F. Hoffmann-La Roche Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. UCB S.A.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Johnson & Johnson Services, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Amgen, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1755

About Us

Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.

From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.

Contact Us:                  

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Show More

Janet Edward

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

Related Articles

Back to top button